Dexamethasone 0.1% / Tobramycin 0.3% eye drops
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Dexamethasone + Tobramycin
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
12 branded products available
MHRA licensed products
View all licensed products for Dexamethasone + Tobramycin on the MHRA register
Tobradex 3mg/ml / 1mg/ml eye drops
Dexamethasone 0.1% / Tobramycin 0.3% eye drops
Dexamethasone 0.1% / Tobramycin 0.3% eye drops
Dexamethasone 0.1% / Tobramycin 0.3% eye drops
Dexamethasone 0.1% / Tobramycin 0.3% eye drops
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 4 · Randomised trials: 7 · 1993–2026
Showing the 50 most relevant studies, sorted by most relevant.
Lan Ke, Yanning Yang
2017
Shah C, Goodman CF, Sen A, et al.
2025
- Eye Infections, Viral
- Conjunctivitis, Viral
- Dexamethasone
Christy M. Isler, P.Scott Barrilleaux, Everett F. Magann, et al.
American Journal of Obstetrics and Gynecology, 2001
C. Cagini, M. Mariniello, M. Messina, et al.
International Ophthalmology, 2020
Min-jie Chen, Lan Gong, Xinghuai Sun, et al.
Current Medical Research and Opinion, 2012
Paul D. Trautman, Heino F.L. Meyer-Bahlburg, Jill Postelnek, et al.
Psychoneuroendocrinology, 1995
I. Chatziralli, L. Papazisis, T. Sergentanis
Ophthalmologica, 2010
Hu G, Li J, Fu L, et al.
2026
- Drug Hypersensitivity
- Hypersensitivity, Delayed
- Anaphylaxis
BackgroundMannitol is Food and Drug Administration-approved for the reduction of intracranial pressure associated with cerebral edema and the reduction of intraocular pressure and is a commonly used drug in clinical practice. Hypersensitivity to mannitol is rarely reported, and only nine cases have been documented in English since 1967, all of which exhibited a rapid onset. We report a case of delayed anaphylactic shock induced by mannitol, aiming to alert clinical practitioners to the potential occurrence of such rare and serious adverse drug reactions (ADRs).Case presentationA 62-year-old Asian Chinese male patient was administered mannitol to reduce intraocular pressure following eye trauma. He did not report any discomfort during the first five intravenous infusions of mannitol. However, upon the sixth administration, the patient presented with anaphylactic shock, characterized by an abrupt loss of consciousness and hypotension. In response, the intravenous infusion was promptly discontinued, and a balanced salt solution was administered for fluid replacement. Epinephrine was administered to elevate blood pressure, while dexamethasone was utilized for its properties of inhibiting allergic responses. Subsequently, the patient's level of consciousness and blood pressure stabilized.DiscussionWe examined the correlation between anaphylactic shock in patients and mannitol, providing a concise summary of the characteristics noted in previous reports of mannitol-induced allergies. Additionally, we highlighted the distinctions of this particular case through a comprehensive literature review, as well as exploring the potential mechanisms behind delayed drug hypersensitivity reactions attributed to mannitol.ConclusionIt is crucial to be aware of the delayed allergic reactions associated with mannitol. Further post-marketing surveillance studies are necessary to identify rare and unknown adverse drug reactions following therapy with mannitol.
Abstract licence: CC BY-NC-ND
Basher H, Eltahir EA, Abdallah MA, et al.
2025
Onsiri Thanathanee, Phornrak Sriphon, Orapin Anutarapongpan, et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2015
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.